Patents by Inventor Chitase Lee

Chitase Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150225397
    Abstract: The present application relates to: (a) compounds of Formula (I): and salts thereof, wherein R1, R2, R3, R4, R5, R6, m, n, X and Y are as defined in the specification; (b) compositions comprising such compounds and salts; and (c) methods of use of such compounds, salts, and compositions, particularly use for the treatment and prevention of diseases such as those associated with oxidative stress and inflammation.
    Type: Application
    Filed: January 23, 2015
    Publication date: August 13, 2015
    Inventors: Pamela Donner, Rolf Wagner, Jason Shanley, Howard Heyman, Allan Krueger, Hui-Ju Chen, Michael Rozema, David Grampovnik, Melean Visnick, Eric Anderson, Xin Jiang, Christopher F. Bender, Gary Louis Bolton, Bradley William Caprathe, Chitase Lee, William Howard Roark
  • Publication number: 20140051739
    Abstract: Disclosed herein are novel antioxidant inflammation modulators, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds and compositions thereof are also provided.
    Type: Application
    Filed: July 11, 2013
    Publication date: February 20, 2014
    Inventors: Eric ANDERSON, Gary L. BOLTON, Bradley CAPRATHE, Xin JIANG, Chitase LEE, William H. ROARK, Melean VISNICK
  • Patent number: 8513436
    Abstract: Disclosed herein are novel antioxidant inflammation modulators, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds and compositions thereof are also provided.
    Type: Grant
    Filed: December 19, 2011
    Date of Patent: August 20, 2013
    Assignee: Reata Pharmaceuticals, Inc.
    Inventors: Eric Anderson, Gary L. Bolton, Bradley Caprathe, Xin Jiang, Chitase Lee, William H. Roark, Melean Visnick
  • Publication number: 20120196880
    Abstract: Disclosed herein are novel antioxidant inflammation modulators, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds and compositions thereof are also provided.
    Type: Application
    Filed: December 19, 2011
    Publication date: August 2, 2012
    Inventors: Eric Anderson, Gary L. Bolton, Bradley Caprathe, Xin Jiang, Chitase Lee, William H. Roark, Melean Visnick
  • Publication number: 20100029710
    Abstract: Compounds of following formula (I) are provided that have both angiotensin II receptor antagonist activity and PPARy agonist activity. Also provided are pharmaceutical compositions comprising the compounds and methods of treatment of diseases with the compounds including type 2 diabetes, insulin resistance, hyperinsulinemia, hyperlipidemia, hypertriglyceridemia, metabolic syndrome, congestive heart failure, and hypertension.
    Type: Application
    Filed: December 3, 2007
    Publication date: February 4, 2010
    Applicant: Pfizer Products Inc.
    Inventors: Christopher Franklin Bigge, Agustin Casimiro-Garcia, Chitase Lee, Hud Lawrence Risley, Robert Philip Schaum
  • Patent number: 7244763
    Abstract: This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.
    Type: Grant
    Filed: February 6, 2004
    Date of Patent: July 17, 2007
    Assignee: Warner Lambert Company LLC
    Inventors: Larry D. Bratton, Xue-Min Cheng, Noe Erasga, Gary F. Filzen, Andrew G. Geyer, Chitase Lee, Bharat K. Trivedi, Paul C. Unangst
  • Patent number: 7109222
    Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.
    Type: Grant
    Filed: December 24, 2004
    Date of Patent: September 19, 2006
    Assignee: Warner-Lambert Company, LLC
    Inventors: Xue-Min Cheng, Gary F. Filzen, Andrew G. Geyer, Chitase Lee, Bharat K. Trivedi
  • Publication number: 20050154042
    Abstract: HMGCo-A reductase inhibitor compounds useful as hypocholesterolemic and hypolipidemic compounds are provided. Also provided are pharmaceutical compositions of the compounds. Methods of making and methods of using the compounds are also provided.
    Type: Application
    Filed: December 2, 2004
    Publication date: July 14, 2005
    Inventors: Larry Bratton, Xue-Min Cheng, Chitase Lee, Steven Miller, Jeffrey Pfefferkorn, Toni-Jo Poel, Roderick Sorenson, Yuntao Song, Kuai-Lin Sun, Bharat Trivedi, Paul Unangst
  • Publication number: 20050113422
    Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.
    Type: Application
    Filed: December 22, 2004
    Publication date: May 26, 2005
    Inventors: Xue-Min Cheng, Gary Filzen, Andrew Geyer, Chitase Lee, Bharat Trivedi
  • Publication number: 20050107442
    Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.
    Type: Application
    Filed: December 24, 2004
    Publication date: May 19, 2005
    Inventors: Xue-Min Cheng, Gary Filzen, Andrew Geyer, Chitase Lee, Bharat Trivedi
  • Patent number: 6867224
    Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.
    Type: Grant
    Filed: December 19, 2002
    Date of Patent: March 15, 2005
    Assignee: Warner-Lambert Company
    Inventors: Xue-Min Cheng, Gary F. Filzen, Andrew G. Geyer, Chitase Lee, Bharat K. Trivedi
  • Patent number: 6833380
    Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.
    Type: Grant
    Filed: December 19, 2002
    Date of Patent: December 21, 2004
    Assignee: Warner-Lambert Company, LLC
    Inventors: Xue-Min Cheng, Noe Erasga, Gary Frederick Filzen, Andrew Geyer, Chitase Lee, Bharat Kalidas Trivedi
  • Publication number: 20040209936
    Abstract: This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.
    Type: Application
    Filed: February 6, 2004
    Publication date: October 21, 2004
    Inventors: Larry D. Bratton, Xue-Min Cheng, Noe Erasga, Gary F. Filzen, Andrew G. Geyer, Chitase Lee, Bharat K. Trivedi, Paul C. Unangst
  • Publication number: 20030207916
    Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.
    Type: Application
    Filed: December 19, 2002
    Publication date: November 6, 2003
    Inventors: Xue-Min Cheng, Noe Erasga, Gary Frederick Filzen, Andrew Geyer, Chitase Lee, Bharat Kalidas Trivedi
  • Publication number: 20030207915
    Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.
    Type: Application
    Filed: December 19, 2002
    Publication date: November 6, 2003
    Inventors: Xue-Min Cheng, Gary F. Filzen, Andrew G. Geyer, Chitase Lee, Bharat K. Trivedi
  • Publication number: 20030207924
    Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses methods for making the disclosed compounds.
    Type: Application
    Filed: December 20, 2002
    Publication date: November 6, 2003
    Inventors: Xue-Min Cheng, Noe Erasga, Gary Frederick Filzen, Andrew Geyer, Chitase Lee, Bharat Kalidas Trivedi
  • Publication number: 20030073684
    Abstract: The instant invention is a series of benzothiazine dioxides, or a pharmaceutically acceptable salt thereof, which are potent endothelin A antagonists with profound in vitro activity, and improved syntheses for the Formula 1 1
    Type: Application
    Filed: June 3, 2002
    Publication date: April 17, 2003
    Inventors: Amy Mae Bunker, Xue-Min Cheng, Annette Marian Doherty, Jeremy John Edmunds, Gerald David Kanter, Chitase Lee, Joseph Thomas Repine, Richard William Skeean
  • Patent number: 6545150
    Abstract: The instant invention is a series of benzothiazine dioxides, or a pharmaceutically acceptable salt thereof, which are potent endothelin A antagonists with profound in vitro activity, and improved syntheses for the Formula 1 The compounds are useful in treating elevated levels of endothelin, essential renovascular malignant and pulmonary hypertension, cerebral infarction, cerebral ischemia, congestive heart failure, and subarachnoid hemorrhage.
    Type: Grant
    Filed: December 5, 2001
    Date of Patent: April 8, 2003
    Assignee: Warner-Lambert Company
    Inventors: Amy Mae Bunker, Xue-Min Cheng, Annette Marian Doherty, Jeremy John Edmunds, Gerald David Kanter, Chitase Lee, Joseph Thomas Repine, Richard William Skeean
  • Patent number: 6440962
    Abstract: The instant invention is a series of benzothiazine dioxides, or a pharmaceutically acceptable salt thereof, which are potent endothelin A antagonists with profound in vitro activity, and improved syntheses for the Formula I The compounds are useful in treating elevated levels of endothelin, essential renovascular malignant and pulmonary hypertension, cerebral infarction, cerebral ischemia, congestive heart failure, and subarachnoid hemorrhage.
    Type: Grant
    Filed: March 27, 2001
    Date of Patent: August 27, 2002
    Assignee: Warner-Lambert Company
    Inventors: Amy Mae Bunker, Xue-Min Cheng, Annette Marian Doherty, Jeremy John Edmunds, Gerald David Kanter, Chitase Lee, Joseph Thomas Repine, Richard William Skeean
  • Publication number: 20020094980
    Abstract: The instant invention is a series of benzothiazine dioxides, or a pharmaceutically acceptable salt thereof, which are potent endothelin A antagonists with profound in vitro activity, and improved syntheses for the Formula 1 1
    Type: Application
    Filed: December 5, 2001
    Publication date: July 18, 2002
    Inventors: Amy Mae Bunker, Xue-Min Cheng, Annette Marian Doherty, Jeremy John Edmunds, Gerald David Kanter, Chitase Lee, Joseph Thomas Repine, Richard William Skeean